Oslo, Norway, 12 June 2018: Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), a clinical stage company focused on developing and commercializing immune activating oncology therapies to target, primarily, treatment resistant solid tumors, today hosts a conference call to give an update to its clinical development strategy.
For reference, please see the press release from 11 June 2018 here.The conference call will include a presentation from the company and a Q&A session.
Date: Tuesday 12 June 2018
Time: 08:30 CET
Presenters: CEO Øystein Soug, CMO Magnus Jäderberg and CFO Erik Digman Wiklund
Presentation: 180611 Company update
Call-in numbers:
Norway: +47 2100 2610
Sweden: +46 (0)8 5033 6574
UK +44 (0)330 336 9105
US: +1 323-794-2423
International: +44 (0)330 336 9105
Access code: 9281577
Please make sure to dial in at least 5-10 minutes ahead to complete your registration.
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media and IR enquires:
Andreas Tinglum – Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no
Simon Conway/Stephanie Cuthbert – FTI Consulting (International)
Phone: +44 20 3727 1000
Email: Targovax@fticonsulting.com
About Targovax
Activating the patient’s immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage company focused on developing and commercializing immune activators to target hard to treat solid tumors. Immuno-oncology is currently one of the fastest growing therapeutic fields in medicine.
Targovax’s primary product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, used as potential multi-target, neo-antigen therapeutic cancer vaccines. It has been engineered as an immune activator that selectively targets cancer cells. In phase I trials it has demonstrated immune activation at lesional level which was associated with clinical benefit. ONCOS-102’s lead indication is mesothelioma where the virus is currently being developed in a phase II trial. A second trial, in advanced melanoma, is expected to produce important proof of concept data for checkpoint inhibitor refractory patients.
In addition, Targovax has a neo-antigen cancer vaccine under development targeting tumors that express mutated forms of RAS. Key proof of concept data for the TG platform from a clinical trial of TG01 in resected pancreatic cancer patients showed encouraging overall survival. A next generation product candidate, TG02 is currently being combined with pembrolizumab in a phase I trial in colorectal cancer.
Both platforms are protected by an extensive portfolio of IP, know-how, and have the potential to yield multiple product candidates.